Sarah Cannon Research Institute
Ben Coleman, Ph.D., currently serves as a Personalized Medicine Scientist in Molecular Oncology at Sarah Cannon Research Institute, a position held since July 2023. Prior to this role, Ben was employed as a Senior Analyst and Analyst at Proactive Worldwide from January 2022 to July 2023. Ben's academic background includes a Doctor of Philosophy in Pharmacology from Vanderbilt University, where a dissertation was completed under the guidance of Dr. Brad Grueter from August 2016 to December 2021. Earlier experience includes a Research Technician I position at UT Southwestern Medical Center, focusing on memory enhancement through small interfering peptides, and involvement as an Undergraduate Researcher at Virginia Tech, leading a project on ovarian cancer spheroid formation. Ben holds a Bachelor of Science from Virginia Tech, completed in 2015.
This person is not in any teams
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.